Results 11 to 20 of about 836,249 (298)

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

New England Journal of Medicine, 2021
BACKGROUND Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and ...
N. Munshi, L. Anderson, N. Shah, D. Madduri, J. Berdeja, S. Lonial, N. Raje, Yi Lin, D. Siegel, A. Oriol, P. Moreau, I. Yakoub-Agha, M. Delforge, M. Cavo, H. Einsele, H. Goldschmidt, K. Weisel, A. Rambaldi, D. Reece, F. Petrocca, M. Massaro, Jamie N. Connarn, S. Kaiser, P. Patel, Liping Huang, T. Campbell, K. Hege, J. San-Miguel   +27 more
semanticscholar   +1 more source

Teclistamab in Relapsed or Refractory Multiple Myeloma.

New England Journal of Medicine, 2022
BACKGROUND Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.
P. Moreau, A. Garfall, N. V. D. van de Donk, H. Nahi, J. San-Miguel, A. Oriol, A. Nooka, T. Martin, L. Rosiñol, A. Chari, L. Karlin, L. Benboubker, M. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez-López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S. X. W. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, Rian Van Rampelbergh, A. Banerjee, J. Goldberg, R. Kobos, A. Krishnan, S. Usmani   +33 more
semanticscholar   +1 more source

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Survival is poor among patients with triple-class-exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep ...
P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A. Nooka, S. Manier, N. Callander, L. Costa, R. Vij, N. Bahlis, P. Moreau, S. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Zhihong Yang, L. Favre‐Kontula, Fan Wu, J. Piasecki, M. Cook, S. Giralt   +21 more
semanticscholar   +1 more source

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma.
J. San-Miguel, B. Dhakal, K. Yong, A. Spencer, S. Anguille, M. Mateos, C. Fernández de Larrea, J. Martínez-López, P. Moreau, C. Touzeau, X. Leleu, I. Avivi, M. Cavo, T. Ishida, S. Kim, W. Roeloffzen, N. V. D. van de Donk, D. Dytfeld, S. Sidana, L. Costa, A. Oriol, R. Popat, A. Khan, Y. Cohen, P. Ho, J. Griffin, N. Lendvai, C. Lonardi, A. Slaughter, J. Schecter, Carolyn C. Jackson, K. Connors, Katherine Li, E. Zudaire, Diana Chen, Jane Gilbert, T. Yeh, Sarah Nagle, E. Florendo, L. Pacaud, Nitin Patel, S. Harrison, H. Einsele   +42 more
semanticscholar   +1 more source

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood, 2023
Key Points • Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory LBCL.• Durable responses were associated with expansion of chimeric antigen receptor T cells early after intravenous infusion.
S. Neelapu, C. Jacobson, A. Ghobadi, D. Miklos, L. Lekakis, O. Oluwole, Yi-Chung Lin, I. Braunschweig, B. Hill, J. Timmerman, A. Deol, P. Reagan, P. Stiff, I. Flinn, U. Farooq, A. Goy, P. Mcsweeney, J. Muñoz, T. Siddiqi, J. Chavez, A. Herrera, N. Bartlett, Adrian Bot, R. Shen, Jinghui Dong, Kanwarjit Singh, H. Miao, Jenny J. Kim, Yan Zheng, F. Locke   +29 more
semanticscholar   +1 more source

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Journal of Clinical Oncology, 2022
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months.
T. Martin, S. Usmani, J. Berdeja, M. Agha, A. Cohen, P. Hari, D. Avigan, A. Deol, M. Htut, A. Lesokhin, N. Munshi, E. O’Donnell, A. Stewart, J. Schecter, J. Goldberg, Carolyn C. Jackson, T. Yeh, A. Banerjee, A. Allred, E. Zudaire, W. Deraedt, Y. Olyslager, Changwei Zhou, L. Pacaud, D. Madduri, A. Jakubowiak, Yi Lin, S. Jagannath   +27 more
semanticscholar   +1 more source

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2022
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic ...
Jennifer R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kaźmierczak, N. Lamanna, S. O'brien, C. Tam, L. Qiu, K. Zhou, M. Šimkovič, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, H. Yimer, T. Salmi, M. Wang, L. Fu, Jessica Li, Kenneth Wu, A. Cohen, M. Shadman   +27 more
semanticscholar   +1 more source

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

New England Journal of Medicine, 2020
BACKGROUND Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR)
Michael L. Wang, J. Muñoz, A. Goy, F. Locke, C. Jacobson, B. Hill, J. Timmerman, H. Holmes, S. Jaglowski, I. Flinn, P. Mcsweeney, D. Miklos, J. Pagel, M. Kersten, N. Milpied, H. Fung, M. Topp, R. Houot, A. Beitinjaneh, Weimin Peng, Lianqing Zheng, J. Rossi, R. Jain, A. Rao, P. Reagan   +24 more
semanticscholar   +1 more source

Adequacy and Effectiveness of Watson For Oncology in the Treatment of Thyroid Carcinoma

Frontiers in Endocrinology, 2021
BackgroundIBM’s Watson for Oncology (WFO) is an artificial intelligence tool that trains by acquiring data from the Memorial Sloan Kettering Cancer Center and learns from test cases and experts.
Hyeok Jun Yun, Hee Jun Kim, Soo Young Kim, Yong Sang Lee, Chi Young Lim, Hang-Seok Chang, Cheong Soo Park   +6 more
doaj   +1 more source

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

New England Journal of Medicine, 2019
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, J. Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz   +23 more
semanticscholar   +1 more source